X
    X
    X
    X

    Dyax Corp Public Offering

    Our Business Law lawyers represented Dyax Corp. in its $60,000,000 Public Offering of Common Stock in October 2013. Dyax Corp,.a biopharmaceutical company based in Burlington, Massachusetts, used its patented phage display technology to invent KALBITOR, which it markets and sells for the treatment of acute attacks of hereditary angiodema (HAE). Dyax has also discovered an antibody that it is developing for prophylactic treatment of HAE and potentially other disorders mediated by plasma kallikrein, and it has licensed its phage display technology to other companies that have used it to discover several product candidates that are in late stage clinical trials.

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.